Binding sites on native and multimeric vitronectin exhibit similar affinity for heparin: The influence of self-association and multivalence on ligand binding

Trends in Cardiovascular Medicine

Volumn 8, Issue 3, 1998, Pages 124-131

  Peterson, Cynthia B ^a  

^a UNIVERSITY OF TENNESSEE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; VITRONECTIN;

ANTICOAGULANT THERAPY; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; DRUG PROTEIN BINDING; EXTRACELLULAR MATRIX; LIGAND BINDING; MOLECULAR INTERACTION; PRIORITY JOURNAL; SHORT SURVEY; STOICHIOMETRY; THROMBOSIS; VASCULAR ENDOTHELIUM;

EID: 0031954123     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1050-1738(97)00136-9     Document Type: Article

References (41)

1. Adler P, Wood SJ, Lee YC, Lee RT, Petri WA Jr, Schnaar RL: 1995. High affinity binding of the Entameoba histolytica lectin to polyvalent N-acetylgalactosaminides. J Biol Chem 270:5164-5171.
2. Barnes DW, Reing JE, Amos B: 1985. Heparin-binding properties of human serum spreading factor. J Biol Chem 260:9117-9122.
3. Bittorf SV, Williams EC, Mosher DF: 1993. Alteration of vitronectin: characterization of changes induced by treatment with urea. J Biol Chem 268:24,838-24,846.
4. deBoer HC, Preissner KT, Buona BN, de-Groot PG: 1992. Binding of vitronectin-thrombin-antithrombin III complexes to human endothelial cells is mediated by the heparin binding site of vitronectin. J Biol Chem 267:2264-2268.
5. Gibson AD, Baburaj K, Day DE, Verhamme I, Shore JD, Peterson CB: 1997. The use of fluorescent probes to characterize conformational changes in the interaction between vitronectin and plasminogen activator inhibitor-1. J Biol Chem 272:5112-5121.
6. Gopalakrishnan PV, Karush F: 1974. Antibody affinity. VII. Multivalent interaction of anti-lactoside antibody. J Immunol 113: 769-778.
7. Hayashi M, Akama T, Kono I, Kashiwagi H: 1985. Activation of vitronectin (serum spreading factor) binding of heparin by denaturing agents. J Biochem 98:1135-1138.
8. Hogasen K, Mollnes TE, Harboe M: 1992. Heparin-binding properties of vitronectin are linked to complex formation as illustrated by in vitro polymerization and binding to the terminal complement complex. J Biol Chem 267:23,076-23,082.
9. Ishikawa M, Hayashi M: 1992. Activation of the collagen-binding of endogenous serum vitronectin by heating, urea, and glycosaminoglycans. Biochim Biophys Acta 1121: 173-177.
10. Izumi M, Yamada KM, Hayashi M: 1989. Vitronectin exists in two structurally and functionally distinct forms in human plasma. Biochim Biophys Acta 990:101-108.
11. Kost C, Stuber W, Ehrlich HJ, Pannekoek H, Preissner KT: 1992. Mapping of binding sites for heparin, plasminogen activator inhibitor-1, and plasminogen to vitronectin's heparin-binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin formation. J Biol Chem 267:12,098-12,105.
12. Lane DA, Flynn AM, Pejler G, Lindahl U, Choay J, Preissner KT: 1987. Structural requirements for the neutralization of heparin-like saccharides by complement S protein/vitronectin. J Biol Chem 262: 16,343-16,348.
13. Lawrence DA, Palaniappan S, Stefansson S, et al.: 1997. Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin: implications for the regulation of pericellular proteolysis. J Biol Chem 272: 7676-7680.
14. McGuire EA, Peacock ME, Inhorn RC, Siegel NR, Tollefsen DM: 1988. Phosphorylation of vitronectin by a protein kinase in human plasma: identification of a unique phosphorylation site in the heparin-binding domain. J Biol Chem 263:1942-1945.
15. Morris CA, Underwood PA, Bean PA, Sheehan M, Charlesworth JA: 1994. Relative topography of biologically active domains of human vitronectin: evidence from monoclonal antibody epitope and denaturation studies. J Biol Chem 269:23,845-23,852.
16. Panetti TS, McKeown-Longo PJ: 1993. Receptor-mediated endocytosis of vitronectin is regulated by its conformational state. J Biol Chem 268:11,988-11,993.
17. Peake PW, Greenstein JD, Russell BA, Charlesworth JA: 1996. The behaviour of human vitronectin in vivo: effects of complement activation, conformation and phosphorylation. Clin Exp Immunol 106:416-422.
18. Piskarev VE, Navratil J, Karaskova H, Bezouska K, Kocourek J: 1990. Interaction of egg-white glycoproteins and their oligosaccharides with the monomer and the hexamer of chicken liver lectin: a multivalent oligosaccharide-combining site exist within the carbohydrate-recognition domain. Biochem J 270:755-760.
19. Podack ER, Muller-Eberhard HJ: 1979. Isolation of human S-protein, an inhibitor of the membrane attack complex of complement. J Biol Chem 254:9908-9914.
20. Preissner KT, Muller-Berghaus G: 1986. S protein modulates the heparin-catalyzed inhibition of thrombin by antithrombin III. Eur J Biochem 156:645-650.
21. Preissner KT, Muller-Berghaus G: 1987. Neutralization and binding of heparin by S protein/vitronectin in the inhibition of Factor Xa by antithrombin: involvement of an inducible heparin-binding domain of S-protein/vitronectin. J Biol Chem 262: 12,247-12,253.
22. Preissner KT, Grulich-Henn J, Ehrlich HJ, et al.: 1990. Structural requirements for the extracellular interaction of plasminogen activator inhibitor-1 with endothelial cell matrix-associated vitronectin. J Biol Chem 265:18,490-18,498.
23. Rheinnecker M, Hardt C, Ilag LL, et al.: 1996. Multivalent antibody fragment with high functional affinity for a tumor-associated carbohydrate antigen. J Immunol 152:2989-2997.
24. Ribeiro SM, Schultz-Cherry S, Murphy-Ullrich JE: 1995. Heparin-binding vitronectin up-regulates latent TGF-beta production by bovine aortic endothelial cells. J Cell Sci 108:1553-1561.
25. Rosenblatt S, Bassuk JA, Alpers CE, Sage EH, Timpl R, Preissner KT: 1997. Differential modulation of cell adhesion by interaction between adhesive and counter-adhesive proteins: characterization of the binding of vitronectin to osteonectin (BM40, SPARC). Biochem J 324:311-319.
26. Sane DC, Moser TL, Greenberg CS: 1991. Limited proteolysis of vitronectin by plasmin destroys heparin. Thromb Haemost 66:310-314.
27. Seiffert D, Schleef RR: 1996. Two functionally distinct pools of vitronectin (Vn) in the blood circulation: identification of a heparin-binding competent population of Vn within platelet alpha-granules. Blood 88: 552-560.
28. Seiffert D: 1997. The glycosaminoglycan binding site governs ligand binding to the somatomedin B domain of vitronectin. J Biol Chem 272:9971-9978.
29. Seiffert D, Smith JW: 1997. The cell adhesion domain in plasma vitronectin is cryptic. J Biol Chem 272:13,705-13,710.
30. Stockmann A, Hess S, Declerck P, Timpl R, Preissner KT: 1993. Multimeric vitronectin: identification and characterization of conformation-dependent self-association of the adhesive protein. J Biol Chem 268: 22,874-22,882.
31. Suzuki S, Pierschbacher MD, Hayman EG, Nguyen K, Ohgren Y, Ruoslahti E: 1984. Domain structure of vitronectin: alignment of active sites. J Biol Chem 259:15,307-15,314.
32. Tomasini BR, Mosher DF: 1988. Conformational states of vitronectin: preferential expression of an antigenic epitope when vitronectin is covalently and noncovalently complexed with thrombin-antithrombin III or treated with urea. Blood 72:903-912.
33. Tomasini BR, Owen MC, Fenton JW II, Mosher DF: 1989. Conformational lability of vitronectin: induction of an antigenic change by α-thrombin-serpin complexes and by proteolytically modified thrombin. Biochemistry 28:7617-7623.
34. Tschopp J, Masson D, Schafer S, Peitsch M, Preissner KT: 1988. The heparin binding domain of S-protein/vitronectin binds to complement components C7, C8 and C9 and perform from cytolytic T-cells and inhibits their lytic activities. Biochemistry 27:4103-4109.
35. Underwood PA: 1993. Problems and pitfalls with measurement of antibody affinity using solid phase binding in the ELISA. J Immunol Methods 164:119-130.
36. Underwood PA, Steele JG, Dalton BA: 1993. Effects of polystyrene surface chemistry on the biological activity of solid phase fibronectin and vitronectin, analysed with monoclonal antibodies. J Cell Sci 104:793-803.
37. Volker W, Hess S, Vischer P, Preissner KT: 1993. Binding and processing of multimeric vitronectin by vascular endothelial cells. J Histochem Cytochem 41:1823-1832.
38. Waltz DA, Chapman HA: 1994. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J Biol Chem 269:14,746-14,750.
39. Zhuang P, Blackburn MN, Peterson CB: 1996a. Characterization of the denaturation and renaturation of human plasma vitronectin. I. Biophysical characterization of protein unfolding and multimerization. J Biol Chem 271:14,323-14,332.
40. Zhuang P, Li H, Williams JG, Wagner NV, Seiffert D, Peterson CB: 1996b. Characterization of the denaturation and renaturation of human plasma vitronectin. II. Investigation into the mechanism of formation of multimers. J Biol Chem 271: 14,333-14,343.
41. Zhuang P, Chen AI, Peterson CB: 1997. Native and multimeric vitronectin exhibit similar affinity for heparin: differences in heparin binding properties induced upon denaturation are due to self-association into a multivalent form. J Biol Chem 272:6858-6867.